{
    "relation": [
        [
            "Arms",
            "Experimental: 1 Buprenorphine + Fosamprenavir/Ritonavir",
            "Active Comparator: 2 Control Fosamprenavir/Ritonavir",
            "Experimental: 3 Buprenorphine + Darunavir/Ritonavir",
            "Active Comparator: 4 Control Darunavir/Ritonavir",
            "Experimental: 5 Buprenorphine + Rifampin",
            "Experimental: 6 Buprenorphine + Rifabutin"
        ],
        [
            "Assigned Interventions",
            "Drug: Fosamprenavir/Ritonavir 1400/200 mg once daily for 15 days total Other Name: Lexiva/Norvir Drug: Buprenorphine FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days Other Name: Suboxone",
            "Drug: Fosamprenavir/Ritonavir 1400/200 mg once daily for 15 days total Other Name: Lexiva/Norvir",
            "Drug: Darunavir/Ritonavir 800/100 mg once daily for 15 days total Other Name: Prezista/Norvir Drug: Buprenorphine FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days Other Name: Suboxone",
            "Drug: Darunavir/Ritonavir 800/100 mg once daily for 15 days total Other Name: Prezista/Norvir",
            "Drug: Rifampin 600 mg once daily for 15 days total Drug: Buprenorphine FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days Other Name: Suboxone",
            "Drug: Rifabutin 300 mg once daily for 15 days total Drug: Buprenorphine FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days Other Name: Suboxone"
        ]
    ],
    "pageTitle": "Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/show/NCT00877591?order=286",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990603.54/warc/CC-MAIN-20150728002310-00078-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 855447111,
    "recordOffset": 855434029,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{12410=FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days}",
    "textBeforeTable": "April 2013 (Final data collection date for primary outcome measure) Primary Completion Date: April 2013 Study Completion Date: April 2008 Study Start Date: 63 Enrollment: Effect of ARV or Tuberculosis Medication on Buprenorphine [\u00a0Time\u00a0Frame:\u00a02007-2010\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Primary Outcome Measures: Further study details as provided by University of California, San Francisco: U.S. FDA Resources Tuberculosis Genetic and Rare Diseases Information Center resources: Darunavir\u00a0ethanolate Fosamprenavir\u00a0calcium Fosamprenavir\u00a0sodium Fosamprenavir",
    "textAfterTable": "\u00a0 Show Detailed Description \u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years and older Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 Yes Criteria Inclusion Criteria: Subjects will be in good health as determined by a physical examination and screening laboratory tests and urinalysis, and will meet the criteria of opioid dependence, but will not be physiologically dependent on any other drugs or alcohol; those with history of current binge alcohol use will also be excluded. Subjects will be enrolled in buprenorphine treatment and must be on a stable, standard clinical dose (4-20 mg/d) for at least 2 weeks prior to initiation of pharmacokinetics study. Control subjects who are non-opioid dependent, are not physiologically dependent on any other drugs or alcohol and volunteer for the HIV medications pharmacokinetics studies alone must be in good health as determined by a physical examination and screening",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}